INDIANAPOLIS, Aug. 29, 2017 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) will showcase new data across six different
tumor types at the European Society for Medical Oncology (ESMO)
2017 Congress in Madrid, Spain,
September 8-12, 2017. Notably,
results from Phase 3 studies of abemaciclib and ramucirumab have
been selected for oral presentation during a Presidential
Symposium, which features groundbreaking research that is
potentially practice-changing, on September
10.
"In line with this year's theme of 'integrating science into
oncology for a better patient outcome,' the data being presented at
ESMO demonstrate how we are further developing our foundational
medicines – each rooted in the biology of cancer – to deliver
innovative breakthrough medicines that will make a meaningful
difference to patients and doctors," said Levi Garraway, M.D., Ph.D., senior vice
president, global development and medical affairs, Lilly Oncology.
"We are excited to share new data that shows our progress on
bringing forward abemaciclib as a potential new treatment option
for advanced breast cancer and investigating the use of ramucirumab
in additional tumor types such as advanced or metastatic urothelial
carcinoma."
For the first time, two Lilly molecules will be featured in an
ESMO Presidential Symposium, with data from its MONARCH 3 and RANGE
studies in advanced breast cancer and platinum-refractory
urothelial cancer, respectively. MONARCH 3 is a global Phase 3,
double-blind, placebo-controlled study, which evaluated the
efficacy and safety of abemaciclib in combination with a
nonsteroidal aromatase inhibitor (letrozole or anastrozole) as
initial endocrine-based therapy for postmenopausal women with
advanced breast cancer who have had no prior systemic treatment for
advanced disease. RANGE is a global Phase 3 randomized,
double-blind study evaluating the safety and efficacy of
ramucirumab and docetaxel compared to placebo and docetaxel in
patients with advanced or metastatic urothelial carcinoma whose
disease progressed on or after platinum-based chemotherapy.
All key studies, along with the times and locations of their
data sessions, are highlighted below.
Abemaciclib
- Abstract Title: MONARCH 3: Abemaciclib as initial therapy for
patients with HR+/HER2- advanced breast cancer
-
- Abstract #236O_PR; Presidential Symposium II: Sunday, September 10, 2017; 16:30-16:45 CEST
- Author/Speaker: Angelo Di Leo,
M.D., Hospital of Prato, Instituto Toscano Tumori
- Location: Madrid Auditorium
- Abstract Title: Efficacy and Safety of Abemaciclib Combined
with LY3023414 or Pembrolizumab in Stage IV NSCLC
-
- Abstract #1363P; Poster Session: Saturday, September 9, 2017; 13:15-14:15 CEST
- Author/Speaker: Pilar Garrido
Lopez, M.D., Hospital Universitario Ramón y Cajal
- Location: Hall 8
- Abstract Title: Analysis of overall survival by tumor response
in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6
inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC)
after chemotherapy for advanced disease
-
- Abstract #249P; Poster Session: Monday,
September 11, 2017; 13:15-14:15
CEST
- Author/Speaker: Javier Cortés,
M.D., Vall d'Hebron University Hospital
- Location: Hall 8
- Abstract Title: Abemaciclib plus fulvestrant in patients (pts)
with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer
- an exploratory analysis of MONARCH 2
-
- Abstract #253P; Poster Session: Monday,
September 11, 2017; 13:15-14:15
CEST
- Author/Speaker: Peter Kaufman,
M.D., Dartmouth-Hitchcock Medical Center
- Location: Hall 8
Ramucirumab
- Abstract Title: RANGE: a randomized, double-blind,
placebo-controlled phase 3 study of docetaxel (DOC) with or without
ramucirumab (RAM) in platinum-refractory advanced or metastatic
urothelial carcinoma
-
- Abstract #LBA4; Presidential Symposium II: Sunday, September 10, 2017; 17:30-17:45 CEST
- Author/Speaker: Daniel Petrylak,
M.D., Yale Cancer Center
- Location: Madrid Auditorium
- Abstract Title: Meta-analysis of individual patient safety data
from six randomized, placebo-controlled trials with the
antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
-
- Abstract #1592P; Poster Session: Sunday,
September 10, 2017; 13:15-14:15
CEST
- Author/Speaker: Dirk Arnold,
M.D., Klinik für Tumorbiologie
- Location: Hall 8
- Abstract Title: A Dose-Response Study of Ramucirumab Treatment
in Patients with Gastric Cancer/Gastroesophageal Junction
Adenocarcinoma: Primary Results of 4 Dosing Regimens in the Phase 2
Trial I4T-MC-JVDB
-
- Abstract #698P; Poster Session: Saturday, September 9, 2017; 13:15-14:15 CEST
- Author/Speaker: Jaffer Ajani,
M.D., MD Anderson Cancer Center
- Location: Hall 8
- Abstract Title: Analysis of Angiogenesis Biomarkers for
Ramucirumab (RAM) Efficacy in Patients with Metastatic Colorectal
Cancer (mCRC) from RAISE, a Global, Randomized, Double-Blind, Phase
3 Study
-
- Abstract #555P; Poster Session: Saturday, September 9, 2017; 13:15-14:15 CEST
- Author/Speaker: Josep Tabernero,
M.D., Vall d'Hebron University Hospital
- Location: Hall 8
Sarcoma
- Abstract Title: The Sarcoma Policy Checklist – focusing policy
efforts on sarcoma
-
- Abstract #1493P; Poster Session: Monday,
September 11, 2017; 13:15-14:15
CEST
- Author/Speaker: Bernd Kasper,
M.D., Universitätsmedizin Mannheim
- Location: Hall 8
Notes to Editor
About Lilly Oncology
For more than 50 years,
Lilly has been dedicated to delivering life-changing medicines and
support to people living with cancer and those who care for them.
Lilly is determined to build on this heritage and continue making
life better for all those affected by cancer around the world. To
learn more about Lilly's commitment to people with cancer, please
visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels. P-LLY
© Lilly USA, LLC 2017. ALL
RIGHTS RESERVED.
Lilly Forward-Looking Statement
This press
release contains forward-looking statements (as that term is
defined in the Private Securities Litigation Reform Act of 1995)
about abemaciclib as a potential treatment for patients with breast
cancer and ramucirumab as a potential treatment for patients with
treatment of platinum-refractory urothelial cancer, and reflects
Lilly's current beliefs. However, as with any pharmaceutical
products, there are substantial risks and uncertainties in the
process of development and commercialization. Among other things,
there can be no guarantee that future study results will be
consistent with the results to date or that abemaciclib or
ramucirumab will receive regulatory approvals or be commercially
successful. For further discussion of these and other risks and
uncertainties, see Lilly's most recent Form 10-K and Form 10-Q
filings with the United States Securities and Exchange Commission.
Except as required by law, Lilly undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
Refer
to:
|
Erin Graves;
graves_erin_elissa@lilly.com; 908-541-8257 (media)
|
|
Phil Johnson;
johnson_philip_l@lilly.com; 317-655-6874 (investors)
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/new-phase-3-data-for-abemaciclib-and-ramucirumab-presented-at-esmo-2017-congress-300510436.html
SOURCE Eli Lilly and Company